Modulus Therapeutics’ cover photo
Modulus Therapeutics

Modulus Therapeutics

Biotechnology Research

Seattle, WA 1,047 followers

Transforming Cell Therapy

About us

Modulus is engineering next-generation immune cell therapies, starting with Natural Killer cells rationally designed for the treatment of solid tumors. Modulus’ Convergent Design™ platform combines genetic engineering, machine learning, and high-throughput in vivo screening to systematically converge on optimized cell designs. Modulus is committed to the discovery of cell therapies to treat a broad set of patient populations not currently served by existing treatments and will use its platform to enable partners and develop an internal pipeline of therapeutics.

Website
http://www.modulustherapeutics.com
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Seattle, WA
Type
Privately Held
Founded
2020

Locations

Employees at Modulus Therapeutics

Updates

  • 🚨 New Modulus Therapeutics Preprint 🚨 We've been really interested in reprogramming cell function in response to diverse environmental signals. In this new preprint, we describe our workflow for finding novel switch receptor designs, and how a comprehensive exploration of signaling space yields functions that would be nearly impossible to intuit or design by hand. https://lnkd.in/gCigviZJ Some highlights: - Switch receptors classically convert 'negative' extracellular signals to 'positive' signals. Here, however, we show that this behavior is much more analog than digital. Tuning specific signaling domain combinations yields a spectrum of function across multiple axes such as cytotox and persistence. - To our knowledge, this is the largest pooled screen ever done in NK cells, at 11,131 members, all in primary cells, using functional assays converted to be screening-compatible. - We observe hits from a diverse set of receptor domains, including cytokine receptor domains, and even receptors classically thought of as inhibitory, suggesting that 'tuning' of cell function via signaling is a lot more nuanced than expected if one merely puts receptors into coarse-grained buckets. Hats off to an amazing team that went from zero-to-one on this whole concept incredibly quickly! #celltherapy #nk #syntheticbiology #oncology #autoimmunedisease

Similar pages

Browse jobs

Funding

Modulus Therapeutics 1 total round

Last Round

Seed

US$ 3.5M

See more info on crunchbase